Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00832650 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00832650 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 60 participants.
The verdict
NCT00832650, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
To assess the effect of fesoterodine 8 mg as compared to solifenacin 10 mg on colonic transit.
Interventions
- DRUG placebo
- DRUG solifenacin
- DRUG fesoterodine fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00832650
The ClinicalTrials.gov registry entry for NCT00832650 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00832650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00832650 about?
NCT00832650 is a clinical study titled "Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit". To assess the effect of fesoterodine 8 mg as compared to solifenacin 10 mg on colonic transit.
What is the current status of trial NCT00832650?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2009-04. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00832650?
The interventions under investigation include: placebo (DRUG), solifenacin (DRUG), fesoterodine fumarate (DRUG).
Who is sponsoring clinical trial NCT00832650?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.